Bacterial cell division as a target for new antibiotics

Current Opinion in Microbiology

Volumn 16, Issue 5, 2013, Pages 522-530

  Sass, Peter ^a   Brötz Oesterhelt, Heike ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1B G 1; 5B; 8J; ADEP 1; ADEP 4; ANTIBIOTIC AGENT; BENZAMIDE DERIVATIVE; BERBERINE; CCR 11; CHRYSOPHAENTIN A; COMPOUND 1; COMPOUND 11; CURCUMIN; FTSZ PROTEIN; GUANOSINE TRIPHOSPHATE; GUANOSINE TRIPHOSPHATE DERIVATIVE; LINEZOLID; PC 190723; UNCLASSIFIED DRUG; ZANTRIN Z 3;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACILLUS SUBTILIS; BACTERIAL CELL; BACTERIAL GROWTH; BINDING SITE; CELL CYCLE; CELL DIVISION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; IC 50; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE; REVIEW; SEPTICEMIA; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALIA; BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; CELL DIVISION; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; TREATMENT OUTCOME;

EID: 84887619725     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.07.006     Document Type: Review

References (50)

1. Nordmann P., Naas T., Fortineau N., Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007, 10:436-440.
2. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
3. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46(Suppl. 5):S350-S359.
4. Sass P., Brötz-Oesterhelt H. Bacterial stress responses to antimicrobial agents. Stress Responses in Foodborne Microorganisms 2012, 131-172. Nova Science Publishers Inc. H.C. Wong (Ed.).
5. Gamba P., Veening J.W., Saunders N.J., Hamoen L.W., Daniel R.A. Two-step assembly dynamics of the Bacillus subtilis divisome. J Bacteriol 2009, 191:4186-4194.
6. Adams D.W., Errington J. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. Nat Rev Microbiol 2009, 7:642-653.
7. Erickson H.P., Anderson D.E., Osawa M. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol Mol Biol Rev 2010, 74:504-528.
8. Löwe J., Amos L.A. Crystal structure of the bacterial cell-division protein FtsZ. Nature 1998, 391:203-206.
9. Oliva M.A., Trambaiolo D., Löwe J. Structural insights into the conformational variability of FtsZ. J Mol Biol 2007, 373:1229-1242.
10. Haydon D.J., Stokes N.R., Ure R., Galbraith G., Bennett J.M., Brown D.R., Baker P.J., Barynin V.V., Rice D.W., Sedelnikova S.E., et al. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 2008, 321:1673-1675.
11. Tan C.M., Therien A.G., Lu J., Lee S.H., Caron A., Gill C.J., Lebeau-Jacob C., Benton-Perdomo L., Monteiro J.M., Pereira P.M., et al. Restoring methicillin-resistant Staphylococcus aureus susceptibility to beta-lactam antibiotics. Sci Transl Med 2012, 4:126ra135.
12. Haydon D.J., Bennett J.M., Brown D., Collins I., Galbraith G., Lancett P., Macdonald R., Stokes N.R., Chauhan P.K., Sutariya J.K., et al. Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. J Med Chem 2010, 53:3927-3936.
13. Adams D.W., Wu L.J., Czaplewski L.G., Errington J. Multiple effects of benzamide antibiotics on FtsZ function. Mol Microbiol 2011, 80:68-84.
14. Andreu J.M., Schaffner-Barbero C., Huecas S., Alonso D., Lopez-Rodriguez M.L., Ruiz-Avila L.B., Nunez-Ramirez R., Llorca O., Martin-Galiano A.J. The antibacterial cell division inhibitor PC190723 is an FtsZ polymer-stabilizing agent that induces filament assembly and condensation. J Biol Chem 2010, 285:14239-14246.
15. Elsen N.L., Lu J., Parthasarathy G., Reid J.C., Sharma S., Soisson S.M., Lumb K.J. Mechanism of action of the cell-division inhibitor PC190723: modulation of FtsZ assembly cooperativity. J Am Chem Soc 2012, 134:12342-12345.
16. Anderson D.E., Kim M.B., Moore J.T., O'Brien T.E., Sorto N.A., Grove C.I., Lackner L.L., Ames J.B., Shaw J.T. Comparison of small molecule inhibitors of the bacterial cell division protein FtsZ and identification of a reliable cross-species inhibitor. ACS Chem Biol 2012, 7:1918-1928.
17. Matsui T., Yamane J., Mogi N., Yamaguchi H., Takemoto H., Yao M., Tanaka I. Structural reorganization of the bacterial cell-division protein FtsZ from Staphylococcus aureus. Acta Crystallogr D: Biol Crystallogr 2012, 68:1175-1188.
18. Stokes N.R., Baker N., Bennett J.M., Berry J., Collins I., Czaplewski L.G., Logan A., Macdonald R., Macleod L., Peasley H., et al. An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. Antimicrob Agents Chemother 2013, 57:317-325.
19. Schaffner-Barbero C., Martin-Fontecha M., Chacon P., Andreu J.M. Targeting the assembly of bacterial cell division protein FtsZ with small molecules. ACS Chem Biol 2012, 7:269-277.
20. Rai D., Singh J.K., Roy N., Panda D Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. Biochem J 2008, 410:147-155.
21. Mishra S., Narain U., Mishra R., Misra K. Design, development and synthesis of mixed bioconjugates of piperic acid-glycine, curcumin-glycine/alanine and curcumin-glycine-piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 2005, 13:1477-1486.
22. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
23. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
24. Kaur S., Modi N.H., Panda D., Roy N. Probing the binding site of curcumin in Escherichia coli and Bacillus subtilis FtsZ - a structural insight to unveil antibacterial activity of curcumin. Eur J Med Chem 2010, 45:4209-4214.
25. Kumar K., Awasthi D., Lee S.Y., Zanardi I., Ruzsicska B., Knudson S., Tonge P.J., Slayden R.A., Ojima I. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J Med Chem 2011, 54:374-381.
26. Plaza A., Keffer J.L., Bifulco G., Lloyd J.R., Bewley C.A. Chrysophaentins A-H, antibacterial bisdiarylbutene macrocycles that inhibit the bacterial cell division protein FtsZ. J Am Chem Soc 2010, 132:9069-9077.
27. Kelley C., Zhang Y., Parhi A., Kaul M., Pilch D.S., LaVoie E.J. 3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents. Bioorg Med Chem 2012, 20:7012-7029.
28. Singh P., Jindal B., Surolia A., Panda D. A rhodanine derivative CCR-11 inhibits bacterial proliferation by inhibiting the assembly and GTPase activity of FtsZ. Biochemistry 2012, 51:5434-5442.
29. Margalit D.N., Romberg L., Mets R.B., Hebert A.M., Mitchison T.J., Kirschner M.W., RayChaudhuri D Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc Natl Acad Sci U S A 2004, 101:11821-11826.
30. Domadia P.N., Bhunia A., Sivaraman J., Swarup S., Dasgupta D. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 2008, 47:3225-3234.
31. Boberek J.M., Stach J., Good L. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS ONE 2010, 5:e13745.
32. Zhang S.L., Chang J.J., Damu G.L., Fang B., Zhou X.D., Geng R.X., Zhou C.H. Novel berberine triazoles: synthesis, antimicrobial evaluation and competitive interactions with metal ions to human serum albumin. Bioorg Med Chem Lett 2013, 23:1008-1012.
33. Parhi A., Lu S., Kelley C., Kaul M., Pilch D.S., LaVoie E.J. Antibacterial activity of substituted dibenzo[a,g]quinolizin-7-ium derivatives. Bioorg Med Chem Lett 2012, 22:6962-6966.
34. Li Z., Garner A.L., Gloeckner C., Janda K.D., Carlow C.K. Targeting the Wolbachia cell division protein FtsZ as a new approach for antifilarial therapy. PLoS Negl Trop Dis 2011, 5:e1411.
35. Taylor M.J., Bandi C., Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005, 60:245-284.
36. Michel KH, Kastner RE: A54556 antibiotics and process for production thereof. US Patent 1985, US patent 4,492,650.
37. Hinzen B., Raddatz S., Paulsen H., Lampe T., Schumacher A., Häbich D., Hellwig V., Benet-Buchholz J., Endermann R., Labischinski H., et al. Medicinal chemistry optimization of acyldepsipeptides of the enopeptin class antibiotics. ChemMedChem 2006, 1:689-693.
38. Brötz-Oesterhelt H., Beyer D., Kroll H.P., Endermann R., Ladel C., Schroeder W., Hinzen B., Raddatz S., Paulsen H., Henninger K., et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med 2005, 11:1082-1087.
39. Schiefer A., Vollmer J., Lammer C., Specht S., Lentz C., Ruebsamen-Schaeff H., Brötz-Oesterhelt H., Hoerauf A., Pfarr K. The ClpP peptidase of Wolbachia endobacteria is a novel target for drug development against filarial infections. J Antimicrob Chemother 2013, (Epub ahead of print). 10.1093/jac/dkt1105.
40. Ollinger J., O'Malley T., Kesicki E.A., Odingo J., Parish T. Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target. J Bacteriol 2012, 194:663-668.
41. Kirstein J., Moliere N., Dougan D.A., Turgay K. Adapting the machine: adaptor proteins for Hsp100/Clp and AAA+ proteases. Nat Rev Microbiol 2009, 7:589-599.
42. Alexopoulos J.A., Guarne A., Ortega J. ClpP: a structurally dynamic protease regulated by AAA+ proteins. J Struct Biol 2012, 179:202-210.
43. Brötz-Oesterhelt H., Sass P. Bacterial caseinolytic proteases as novel targets for antibacterial treatment. Int J Med Microbiol 2013, (Special Issue on Novel Antiinfectives).
44. Kirstein J., Hoffmann A., Lilie H., Schmidt R., Rübsamen-Waigmann H., Brötz-Oesterhelt H., Mogk A., Turgay K. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol Med 2009, 1:37-49.
45. Lee B.G., Park E.Y., Jeon H., Sung K.H., Paulsen H., Rübsamen-Schaeff H., Brötz-Oesterhelt H., Song H.K. Structures of ClpP in complex with a novel class of antibiotics reveal its activation mechanism. Nat Struct Mol Biol 2010, 17:471-478.
46. Li D.H., Chung Y.S., Gloyd M., Joseph E., Ghirlando R., Wright G.D., Cheng Y.Q., Maurizi M.R., Guarne A., Ortega J. Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP. Chem Biol 2010, 17:959-969.
47. Leung E., Datti A., Cossette M., Goodreid J., McCaw S.E., Mah M., Nakhamchik A., Ogata K., El B.M., Cheng Y.Q., et al. Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease. Chem Biol 2011, 18:1167-1178.
48. Sass P., Josten M., Famulla K., Schiffer G., Sahl H.G., Hamoen L., Brötz-Oesterhelt H. Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ. Proc Natl Acad Sci U S A 2011, 108:17474-17479.
49. Raju R.M., Goldberg A.L., Rubin E.J. Bacterial proteolytic complexes as therapeutic targets. Nat Rev Drug Discov 2012, 11:777-789.
50. Raju R.M., Unnikrishnan M., Rubin D.H., Krishnamoorthy V., Kandror O., Akopian T.N., Goldberg A.L., Rubin E.J. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog 2012, 8:e1002511.